CBX6 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL30315936	1.00	1/20
SCHEMBL29613505	0.91	1/20
SCHEMBL27223064	0.89	1/20
SCHEMBL27232005	0.89	1/20
SCHEMBL23682719	0.73	1/20
SCHEMBL23682865	0.73	1/20
SCHEMBL23717921	0.73	1/20
SCHEMBL23718040	0.73	1/20
SCHEMBL26219950	0.73	1/20
SCHEMBL29613468	0.71	1/20
SCHEMBL29613457	0.71	1/20
SCHEMBL24511108	0.68	1/20
SCHEMBL23718039	0.64	1/20
SCHEMBL23815796	0.64	1/20
SCHEMBL23815561	0.64	1/20
SCHEMBL24510752	0.64	1/20
SCHEMBL23682687	0.63	1/20
SCHEMBL23815823	0.63	1/20
SCHEMBL24510644	0.63	1/20
SCHEMBL29613443	0.63	1/20

Clinical trials — most relevant to CBX6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	PHASE2	COMPLETED
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer	PHASE1/PHASE2	SUSPENDED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer	PHASE1/PHASE2	WITHDRAWN
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma	PHASE2	ACTIVE_NOT_RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
The Danish TURNER Cryopreservation Study	nan	RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Characterization of At-risk Population for Pre-sacral Tumor in CURRARINO Syndrome	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Gene Mutations and Rescue in Human Congenital Diaphragmatic Hernia	nan	UNKNOWN
Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes	nan	ACTIVE_NOT_RECRUITING
Immunophenotyping and Xist Gene in AML	nan	UNKNOWN
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants	nan	RECRUITING
Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.	nan	RECRUITING
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.	nan	UNKNOWN
Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science	nan	RECRUITING
The Role of TBX3 in Human ES Cell Differentiation	nan	WITHDRAWN
Tissue Bank of Biological Specimens From Patients With Gynecologic Disease	nan	UNKNOWN
Chordoma Family Study	nan	COMPLETED
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies	nan	WITHDRAWN
Patients With RETT Syndrome	nan	UNKNOWN
Familial Investigations of Childhood Cancer Predisposition	nan	RECRUITING
Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children	nan	COMPLETED
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Cause of Familial Testicular Cancer	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CBX6 binder may also engage these)

Protein	Name	Similarity
Q9DBY5	—	1.000	Q9DBY5 →
CBX4	E3 SUMO-protein ligase CBX4	1.000	landscape →
P48435	—	0.998	P48435 →
Q9P1Z0	—	0.996	Q9P1Z0 →
Q5TGY3	—	0.996	Q5TGY3 →
D6RIA3	—	0.995	D6RIA3 →
Q63624	—	0.994	Q63624 →
Q80WT2	—	0.994	Q80WT2 →
Q9QXV1	—	0.994	Q9QXV1 →
Q8BSD5	—	0.994	Q8BSD5 →
Q9Z0Y7	—	0.994	Q9Z0Y7 →
P70459	—	0.994	P70459 →
Q2VWA4	—	0.994	Q2VWA4 →
P24899	—	0.994	P24899 →
Q96RK0	—	0.994	Q96RK0 →
Q5VZ18	—	0.994	Q5VZ18 →
P55200	—	0.993	P55200 →
A7X8B7	—	0.993	A7X8B7 →
Q00587	—	0.993	Q00587 →
D4A8X0	—	0.993	D4A8X0 →
Q86V15	—	0.993	Q86V15 →
Q9P1Y6	—	0.993	Q9P1Y6 →
O95886	—	0.993	O95886 →
A7X8B3	—	0.993	A7X8B3 →
Q8CGW4	—	0.993	Q8CGW4 →
KDM3B	Lysine-specific demethylase 3B	0.993	landscape →
A2A9A2	—	0.993	A2A9A2 →
P81067	—	0.992	P81067 →
P50548	—	0.992	P50548 →
P84551	—	0.992	P84551 →